Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics, Plc is changing the ratio of its American Depositary Shares to ordinary shares from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares. This ratio change produces a one-for-forty reverse split of the issued and outstanding ADSs only.
The ratio change is expected to be effective on or about March 31, 2026 and is intended to help the company maintain compliance with Nasdaq’s minimum bid price requirement. The company’s underlying ordinary shares are unchanged, and the ADSs will continue to trade on the Nasdaq Capital Market under the symbol AKTX.
No fractional new ADSs will be issued. Instead, fractional entitlements will be aggregated and sold, and net cash proceeds after fees, taxes and expenses will be distributed to affected ADS holders by the depositary bank, Deutsche Bank.
Akari Therapeutics director Neal James increased his economic exposure to the company on December 16, 2025 by acquiring derivative securities tied to its American Depositary Shares (ADSs).
He obtained a total of 11,132 warrants and pre-funded warrants to purchase ADSs through a private placement and a note cancellation and exchange agreement. The PIPE pre-funded warrants and accompanying Series G Warrants, as well as additional note-exchange warrants, are exercisable only upon shareholder approval. The pre-funded warrants carry a stated conversion exercise price of $0.00001 per ADS.
Akari Therapeutics investor Ray Prudo has updated his ownership in a Schedule 13D/A Amendment No. 10. He is reported to beneficially own 8,391,326,467 ordinary shares, representing 8.9% of Akari’s ordinary shares, based on 91,567,009,533 shares outstanding as of March 1, 2026.
The filing reflects December 17, 2025 transactions where Dr. Prudo purchased Series G Warrants and Pre-Funded Warrants in a private placement and additional Note Exchange Warrants and Pre-Funded Warrants in a note cancellation and exchange, all at a combined price of $0.4041 per warrant pair, using personal funds.
Samir R. Patel reports beneficial ownership of 9,725,215,000 ordinary shares of Akari Therapeutics Plc, representing 10.4% of the company’s ordinary shares outstanding as of March 1, 2026. The shares are tied to Akari’s ordinary shares, which trade in ADS form on Nasdaq under the symbol AKTX.
The stake consists of 285,336,000 ordinary shares held directly by Dr. Patel, 6,062,010,000 shares held through PranaBio Investments LLC, 1,579,785,000 options exercisable within 60 days, and 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days. Dr. Patel manages PranaBio and may be deemed the beneficial owner of its holdings.
The update reflects a December 17, 2025 private placement in which Dr. Patel bought Series G warrants, Note Exchange warrants, and prefunded warrants to purchase ADSs, all funded from his personal funds. Additional warrants for up to 5,450,454,000 shares are excluded because of a 9.99% beneficial ownership limitation.
Akari Therapeutics Plc amendment reports that Hoyoung Huh, M.D., Ph.D. beneficially owned 18,199,697,667 ordinary shares, representing 18.4% of the class based on March 1, 2026 share count. The filing states each ADS represents 2,000 Ordinary Shares and discloses excluded warrants that are "subject to a 9.99% beneficial ownership limitation."
Akari Therapeutics, Plc reported results of a special general meeting where shareholders approved several warrant-related resolutions tied to prior financings and note exchanges. The meeting was held on March 2, 2026, with 91,567,009,533 ordinary shares entitled to vote, and all proposals passed.
Shareholders approved, for Nasdaq Listing Rule 5635(c) and 5635(d) purposes, the exercisability and related issuances for Series G Warrants and Placement Agent Warrants covering up to 10,043,774 and 504,300 American Depositary Shares, respectively. They also approved the exercisability of various Pre-Funded, Series G, and Note Exchange Warrants covering multiple blocks of ADSs issued in December 2025 transactions.
Akari Therapeutics, Plc is asking shareholders to approve the exercisability of several warrant issuances tied to recent financings and a note exchange. Five ordinary resolutions cover Series G Warrants, Pre-Funded Warrants, Note Exchange Warrants and Placement Agent Warrants issued in a registered direct offering, a concurrent private placement and a note exchange completed in December 2025 and January 2026.
The proposals would permit exercise of warrants for up to 10,043,774 ADSs plus 504,300 ADSs from placement agent warrants in the registered direct deal, 5,127,426 ADSs from the private placement, and 19,005,406 ADSs from the note exchange. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised for cash, Akari states it could receive approximately $8.9 million in gross proceeds.
The board unanimously recommends voting in favor of each warrant exercise proposal and explains that without approval, the warrants cannot be exercised and the company would need to call additional shareholder meetings, adding cost. The proxy also explains detailed voting procedures for ordinary shareholders and ADS holders and outlines current major shareholdings.
Akari Therapeutics, Plc is registering up to 34,680,906 American Depositary Shares (ADSs), representing 69,361,812,000 ordinary shares, for resale by existing investors. These ADSs are issuable from a mix of Series G warrants, pre-funded warrants, note exchange warrants and placement agent warrants tied to Akari’s December 2025 registered direct and private offerings and a December 2025 note exchange. Akari is not selling shares itself and will not receive proceeds from investor resales, though it may receive up to $8.9 million if warrants are exercised for cash. As of January 22, 2026, Akari had 45,781,350 ADSs (91,562,700,000 ordinary shares) outstanding plus 4,309,533 ordinary shares not in ADS form. The company is repositioned as an oncology business focused on antibody-drug conjugates, led by preclinical candidate AKTX-101, and reports a long history of operating losses, limited cash (about $2.5 million at September 30, 2025), material weaknesses in internal controls, and significant ongoing capital needs, all highlighted in extensive risk factors.
Akari Therapeutics, Plc is asking shareholders at a March 2, 2026 general meeting to approve five resolutions that would allow the exercise of several series of warrants issued in recent financings and a note exchange, as required under Nasdaq Listing Rules 5635(c) and 5635(d). The warrants relate to a December 2025 registered direct offering of 10,043,774 ADSs with matching Series G Warrants, a concurrent private placement to directors and officers with 2,563,713 Pre-Funded Warrants and 2,563,713 Series G Warrants, and an exchange of about $4 million of 2026 notes into 9,502,703 Pre-Funded Warrants and 9,502,703 Note Exchange Warrants. The board unanimously recommends voting FOR all warrant exercise proposals. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised, Akari states that 80,462,236 ADSs, representing 159,898,691,533 ordinary shares, would be outstanding and the company could receive about $8.9 million in cash proceeds.